San Francisco startup Structure Therapeutics can be working on an oral, when-day-to-day GLP-1 drug named GSBR-1290—the drug surpassed Wall Street’s anticipations in June any time a mid-stage examine confirmed regular weight loss of about 6% and it plans to start A further mid-phase trial toward the end of the yr—that founder and CEO Raymond S